AECB is a recurring , debilitating condition , and patients want to get better as quickly as possible , said Dean Hautamaki , MD , lead author of the study and Associate Director of Clinical Studies , Lung Associates of Sarasota and Director of Critical Care Services at Sarasota Memorial Hospital
.Our findings are good news to both patients and physicians because they show that moxifloxacin effectively treats AECB in just five days , quicker than the approved courses of levofloxacin and other fluoroquinolones , which range from seven to ten days , he
added that the study is the first to directly compare moxifloxacin with levofloxacin for the treatment of AECB.
Study and Findings
The multicenter study employed a prospective , double-blind design to randomly assign adult patients confirmed with AECB to once-daily oral therapy of either moxifloxacin ( 400 mg ) for five days or levofloxacin ( 500 mg ) for seven days.The primary outcome was clinical response at the test-of-cure visit 7 to 21 days after therapy ended ; bacteriological responses were also assessed as a secondary measure.
Among patients who completed the study and were valid for efficacy analysis , the clinical cure rates of those given moxifloxacin ( 227 total ) and levofloxacin ( 234 total ) were statistically equivalent : 93 percent and 94 percent , respectively.